Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Inflammation-mediated memory dysfunction and effects of a ketogenic diet in a murine model of multiple sclerosis.
Nav1.5 sodium channels in macrophages in multiple sclerosis lesions.
Solodyn
Separated at birth? The functional and molecular divergence of OLIG1 and OLIG2.
Solitary sclerosis: Progressive neurological deficit from a spatially isolated demyelinating lesion: A further report.
Teva to initiate third Phase III trial of oral laquinimod for the treatment of relapsing remitting multiple sclerosis
Concurrent saturation transfer contrast in in vivo brain by a uniform magnetization transfer MRI.
Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial.
MS related employment and disease modifying treatment in the German working population: 1994-2009.
Infectious causes of multiple sclerosis.
Placebo? no thanks, it might be bad for me!
Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis.
Rush University Medical Center Sells AMPYRA® Royalty Rights to DRI Capital Managed Fund for Approximately $42 Million
Noninvasive molecular imaging of neuroinflammation.
Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor.
Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis.
The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: Lessons from gene expression signatures.
Multiple sclerosis treatment: current best practice.
Identification of protein networks involved in the disease course of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.
Myelin Basic Protein-Specific TCR/HLA-DRB5*01:01 Transgenic Mice Support the Etiologic Role of DRB5*01:01 in Multiple Sclerosis.
Bayer Receives FDA Approval for BETACONNECT - First and Only Electronic Autoinjector in Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment
JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.
High-dose cyclophosphamide in multiple sclerosis patients undergoing autologous stem cell transplantation.
Lipoatrophy in patients with multiple sclerosis on glatiramer acetate.
Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.

Pages